Mounjaro vs. Ozempic

Are Mounjaro and Ozempic the same drug?

No — they are two different molecules from two different manufacturers. Mounjaro is tirzepatide and Ozempic is semaglutide.

Both are once-weekly injections approved for type 2 diabetes, and both lower blood sugar and reduce weight — but Mounjaro acts on two gut-hormone receptors while Ozempic acts on one, which is the main reason their results differ when they are tested directly against each other [1], [2], [3].

The bigger picture: Mounjaro, Ozempic, Zepbound, Wegovy

It helps to see how the brands line up, because the diabetes and weight-loss versions are easy to confuse:

• Tirzepatide → Mounjaro (type 2 diabetes) and Zepbound (weight management; also obstructive sleep apnea) [1].
• Semaglutide → Ozempic (type 2 diabetes), Wegovy (weight management), and Rybelsus (oral diabetes tablet) [2].

So Mounjaro vs. Ozempic is the diabetes-brand matchup of the same two molecules behind Zepbound vs. Wegovy. The trial evidence carries across.

What is Mounjaro?

Mounjaro (tirzepatide) is a once-weekly injection FDA-approved to improve blood sugar in adults with type 2 diabetes. It is a dual agonist — sometimes called a "twincretin" — that activates both the GIP and GLP-1 receptors, and it titrates from 2.5 mg up to a maximum of 15 mg once weekly.

Mounjaro is not FDA-approved for weight loss; that is the role of its sibling, Zepbound, which contains the same drug [1].

What is Ozempic?

Ozempic (semaglutide) is a once-weekly injection FDA-approved for type 2 diabetes — and, uniquely in this matchup, to reduce the risk of major cardiovascular events in adults with type 2 diabetes and heart disease, and (as of 2025) to slow chronic kidney disease in type 2 diabetes.

It is a single GLP-1 receptor agonist dosed from 0.25 mg up to 2 mg once weekly. Like Mounjaro, Ozempic is widely used off-label for weight loss but is not FDA-approved for it — that is the role of Wegovy [2], [4], [5].

How they work: one hormone vs. two

Both mimic GLP-1, a gut hormone that curbs appetite, slows stomach emptying, and triggers insulin when blood sugar is high [1], [2]. Mounjaro adds a second action on the GIP receptor, a related incretin hormone involved in how the body handles food and energy.

That dual mechanism is the leading explanation for why tirzepatide tends to lower blood sugar and body weight more than a GLP-1-only drug such as semaglutide [3].

Effectiveness: blood sugar and weight

In the head-to-head SURPASS-2 trial, Mounjaro outperformed Ozempic at every dose.

Among 1,879 adults with type 2 diabetes on metformin, after 40 weeks tirzepatide lowered HbA1c by −2.01%, −2.24%, and −2.30% (at 5, 10, and 15 mg) versus −1.86% for semaglutide 1 mg, and cut body weight by −7.6 kg, −9.3 kg, and −11.2 kg versus −5.7 kg — all statistically superior [3].

In plain terms, the highest Mounjaro dose produced roughly 5–6 kg more weight loss and a larger blood-sugar drop than the semaglutide dose used in that trial.

One caveat worth knowing: SURPASS-2 compared Mounjaro against the 1 mg dose of semaglutide (Ozempic's mid-range dose), not the 2 mg maximum. Even so, the direction matches the obesity head-to-head, SURMOUNT-5, where tirzepatide also beat semaglutide (−20.2% vs −13.7% of body weight) [6].

Are they approved for weight loss?

No — neither Mounjaro nor Ozempic is FDA-approved for weight loss, even though both reliably cause it. The FDA-approved weight-management versions are Zepbound (tirzepatide) and Wegovy (semaglutide), which use the same molecules at doses studied specifically for obesity [1], [2].

In their obesity trials, Zepbound produced up to −20.9% of body weight (SURMOUNT-1) and Wegovy −14.9% (STEP 1) [7], [8]. If weight loss is your main goal, those siblings — not the diabetes brands — are the on-label options, though insurance often dictates which you can actually get.

What to expect: timeline

Neither drug works overnight. Both start at a low dose and step up about every 4 weeks, so appetite control and blood-sugar improvements build over months rather than days. In SURPASS-2, the HbA1c and weight changes accrued gradually across the full 40-week period, and weight loss kept building even longer in the obesity studies [3], [6].

Both are long-term treatments for chronic conditions: stop them and appetite returns and blood sugar drifts back up, so they are meant to be taken and supervised over the long run [1], [2].

Heart and kidney protection

This is where Ozempic currently leads. Semaglutide has FDA-approved indications, backed by large trials, to protect the heart and kidneys in type 2 diabetes: in SUSTAIN-6 it cut major adverse cardiovascular events by 26% versus placebo, and in the FLOW trial it reduced major kidney-disease events by 24% [4], [5].

Tirzepatide's cardiovascular-outcomes evidence is still maturing, so for a person with type 2 diabetes who also has heart or kidney disease, Ozempic's proven protection can be the deciding factor [1], [2].

Dosing & administration

Both are once-weekly subcutaneous injections in prefilled pens, started low and stepped up about every 4 weeks to limit nausea [1], [2].

Mounjaro dosing

2.5 mg (start) → 5 → 7.5 → 10 → 12.5 → 15 mg maximum, once weekly [1].

Ozempic dosing

0.25 mg (start) → 0.5 → 1 → 2 mg maximum, once weekly [2].

Side effects & safety

Side effects come from the shared GLP-1 action and are similar for both — predominantly gastrointestinal, usually mild-to-moderate, and worst just after starting or increasing a dose. In SURPASS-2, nausea (17–22% vs 18%), diarrhea, and vomiting were the most common events in both groups [1], [2], [3].

Serious risks & boxed warning

Both carry a boxed warning for thyroid C-cell tumors and are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 [1], [2]. Both can also cause pancreatitis, gallbladder disease, acute kidney injury (often from dehydration), and low blood sugar when combined with insulin or a sulfonylurea [1], [2].

Who should not take these (and key cautions)

Avoid either drug with a personal or family history of MTC or MEN 2, or a prior serious reaction to it [1], [2]. Use caution with a history of pancreatitis or gallbladder disease.

Semaglutide should be stopped at least 2 months before a planned pregnancy because it clears slowly [2], and tirzepatide can make oral birth control less effective — switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase [1]. Tell your clinician your full history before starting.

Cost & insurance coverage

Without insurance, both run roughly $1,000–$1,100 per month at list price [1], [2]. Coverage is the deciding factor: because both are approved for type 2 diabetes, insurers more often cover them for that diagnosis than for weight loss.

Manufacturer savings programs and self-pay options can lower the real cost, and a supervised medical weight-loss program like JumpstartMD's can change what you actually pay.

A note on compounded versions: compounded GLP-1 medications can be a lower-cost route, and the rules around them shifted as the recent shortages resolved [9]. Quality and physician oversight vary by source, so a compounded option should come from a licensed, supervised medical program using a reputable compounding pharmacy — not an anonymous online seller.

JumpstartMD prescribes and supervises these medications, including compounded options where appropriate.

Can you switch between them?

Yes — switching is common and is done under medical supervision. Because they are different molecules and are not milligram-equivalent, a clinician restarts the dose ladder for the new drug rather than matching doses, and manages side effects through the re-titration.

You should not take both together — combining tirzepatide with a GLP-1 drug like semaglutide is not recommended [1].

Which is right for you?

• You want the strongest blood-sugar and weight reduction → Mounjaro won the head-to-head (SURPASS-2) [3].
• You have heart disease or kidney disease with diabetes → Ozempic has the proven cardiovascular and kidney benefit [4], [5].
• Your main goal is weight loss → ask about the on-label siblings, Zepbound or Wegovy, rather than the diabetes brands [7], [8].
• Coverage is the obstacle → the answer often comes down to which one your plan will pay for.

The right choice depends on your diagnosis, other conditions, insurance, and history — exactly what a supervised consultation sorts out. JumpstartMD physicians prescribe and manage both Mounjaro and Ozempic (and their weight-management siblings), including dose titration and side-effect management.